TAG’s 2025 Pipeline Report: TB Treatment

Treatment Action Group (TAG) released the latest edition of its Tuberculosis Treatment Pipeline Report, written by TB Project co-director Lindsay McKenna.

The only centralized resource of its kind, the TB Treatment Pipeline Report is for researchers, clinicians, drug sponsors, research funders, civil society, and TB-affected communities looking to better understand the state of the TB treatment pipeline.

The report provides the latest information on 22 new or repurposed drugs in clinical development for TB and summarizes ongoing, planned, and recently completed trials. Included in this year’s report are:

• Results from the phase 3 endTB-Q trial and two phase 2b/c trials of quabodepistat-containing regimens completed or discontinued in 2024;
• First-of-their-kind trials focused on asymptomatic TB and bedaquiline-resistant TB;
• The first long-acting formulation of a TB drug to enter clinical development; and
• The first phase 3 trial of a new drug from a new class since bedaquiline and delamanid.

United States Government research funding cuts, suspensions, and interruptions that began in January 2025 threaten this and other progress, including work important to closing research gaps for priority populations and to delivering a new wave of treatment advances. McKenna’s coverage of the pipeline demonstrates what’s at risk and serves as a call to action to preserve scientific advances underway and bolster research infrastructure that’s been jeopardized by the current US administration.

Earlier this year TAG published the latest editions of its TB Diagnostics Pipeline Report and TB Vaccines Pipeline Report.

For more TB updates, check out the TB CAB Weekly Newsletter (Issue #26, 19 August 2025).

The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and EATG. Subscribe to the newsletter here.